<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>24A. Hypersensitivity Reactions</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="immunology-23c-secondary-immunodeficiency-details.html" class="nav-button"> 
                        <span class="nav-icon"></span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 84.62%;"></div> <!-- (33/39)*100 -->
                        </div>
                       <span class="progress-text">Lecture 33 of 39</span> 
                    </div>
                    <a href="immunology-24b-type1-hypersensitivity.html" class="nav-button"> 
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon"></span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">Hypersensitivity reactions</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                <!-- START: section-teaching-objectives -->
                <section id="section-teaching-objectives" class="content-section" aria-labelledby="section-heading-teaching-objectives">
                    <h2 id="section-heading-teaching-objectives" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">TEACHING OBJECTIVES</span>
                    </h2>
                    <div class="content-card">
                        <ol>
                            <li>Understand the classification of hypersensitivity reactions</li>
                            <li>Know the diseases associated with hypersensitivity reactions</li>
                            <li>Understand the mechanisms of damage in hypersensitivity reactions</li>
                            <li>Know the methods for diagnosing conditions due to hypersensitivity</li>
                            <li>Know the modes of treating disease due to hypersensitivity and their rationale</li>
                        </ol>
                    </div>
                </section>
                <!-- END: section-teaching-objectives -->

                <!-- START: section-hypersensitivity-reactions-intro -->
                <section id="section-hypersensitivity-reactions-intro" class="content-section" aria-labelledby="section-heading-hypersensitivity-reactions-intro">
                    <h2 id="section-heading-hypersensitivity-reactions-intro" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Hypersensitivity Reactions</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Undesirable (damaging, discomfort producing and sometimes fatal) reactions produced by the normal immune system.</li>
                            <li>require a pre-sensitized (immune) state of the host.</li>
                            <li><strong>Gell and Coombs classification:</strong>
                                <ul>
                                    <li>four types: type I, type II, type III and type IV</li>
                                    <li>based on the mechanisms involved and time taken for the reaction.</li>
                                    <li>Frequently, a particular clinical condition (disease) may involve more than one type of reaction.</li>
                                </ul>
                            </li>
                        </ul>
                        <ol>
                            <li><strong>Immediate hypersensitivity reactions</strong>
                                <ul>
                                    <li>result from an AMI based interaction (antibody- antigen)</li>
                                    <li>take minutes to hours to develop after first encounter with antigen</li>
                                    <li>Type I. Type II. and Type III.</li>
                                </ul>
                            </li>
                            <li><strong>Delayed hypersensitivity reactions</strong>
                                <ul>
                                    <li>result from an CMI based interaction (cell-cell)</li>
                                    <li>symptoms do not develop for days after exposure to antigen</li>
                                    <li>Type IV</li>
                                </ul>
                            </li>
                        </ol>
                        <figure>
                            <img src="../assets/images/2025_06_15_a488c342de18e7acee23g-05-1.jpg" alt="Diagram illustrating the four types of hypersensitivity reactions (Gell and Coombs classification). Type I: IgE-mediated, mast cell degranulation. Type II: Antibody-mediated cytotoxicity against cell surface antigens. Type III: Immune complex-mediated. Type IV: T-cell mediated delayed hypersensitivity." class="content-image">
                            <figcaption>Figure 10.1a - Overview of Hypersensitivity Reactions</figcaption>
                        </figure>
                    </div>
                </section>
                <!-- END: section-hypersensitivity-reactions-intro -->

                <!-- START: section-type-i-hypersensitivity -->
                <section id="section-type-i-hypersensitivity" class="content-section" aria-labelledby="section-heading-type-i-hypersensitivity">
                    <h2 id="section-heading-type-i-hypersensitivity" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Type I Hypersensitivity: Sensitization</span>
                    </h2>
                    <div class="content-card">
                        <figure>
                            <img src="../assets/images/2025_06_15_a488c342de18e7acee23g-06-1.jpg" alt="Diagram illustrating the sensitization phase of Type I hypersensitivity. Allergen is processed by APC, presented to Th2 cell, which helps B cell produce IgE. IgE binds to Fc receptors on mast cells." class="content-image">
                        </figure>
                        <figure>
                            <img src="../assets/images/2025_06_15_a488c342de18e7acee23g-07-1.jpg" alt="Another diagram showing Type I sensitization: Allergen exposure leads to Th2 activation, IL-4 production, B cell class switching to IgE, and IgE binding to mast cells." class="content-image">
                        </figure>
                        <h3 class="subsection-heading">Type I Hypersensitivity: Effector Phase</h3>
                        <figure>
                            <img src="../assets/images/2025_06_15_a488c342de18e7acee23g-08-1.jpg" alt="Diagram of the effector phase of Type I hypersensitivity. Re-exposure to allergen cross-links IgE on sensitized mast cell, leading to degranulation and release of mediators (histamine, leukotrienes, prostaglandins)." class="content-image">
                        </figure>
                        <figure>
                            <img src="../assets/images/2025_06_15_a488c342de18e7acee23g-09-1.jpg" alt="Detailed illustration of mast cell degranulation in Type I hypersensitivity. Allergen cross-linking IgE triggers release of preformed mediators (histamine, proteases) and synthesis of newly formed mediators (leukotrienes, prostaglandins, cytokines)." class="content-image">
                            <figcaption>Figure 7.24 ©2000 Garland Publishing/Elsevier Science</figcaption>
                        </figure>
                        <h3 class="subsection-heading">Preformed Mediators:</h3>
                        <ol>
                            <li>Stored in granules in mast cells</li>
                            <li><strong>Histamine</strong> - most important mediator in humans, although a similar function is performed by serotonin in other species, e.g., rodents
                                <ul>
                                    <li>most of the characteristics of anaphylaxis can be mimicked in humans by injection of histamine alone</li>
                                    <li>present in granules at very high concentrations as an electrostatic complex with heparin. After fusion of the granules histamine is released from the heparin complex by ion-exchange effects</li>
                                    <li>stimulates contraction in most smooth muscle, vasodilation and permeability in post-capillary venules, drop in blood pressure</li>
                                </ul>
                            </li>
                            <li><strong>Eosinophil chemotactic factor</strong> - attracts and prevents further migration of eosinophils and neutrophils</li>
                            <li><strong>Neutrophil chemotactic factor</strong> - attracts and prevents further migration of neutrophils</li>
                            <li><strong>Degradative enzymes including:</strong> Arylsulfatase - inactivates leukotrienes, chymase - degrades proteins, N acetylglucosaminidase - degrades heparin</li>
                        </ol>
                        <h3 class="subsection-heading">Causes and Results</h3>
                        <ul>
                            <li>for humans can result from, bee or wasp sting, seafood, nuts.</li>
                            <li>can also result from cross linking of drug to self protein (i.e., penicillin, insulin)</li>
                            <li>can result in asthma, hay fever, systemic or localized anaphylaxis</li>
                        </ul>
                        <h3 class="subsection-heading">Lipid Mediators:</h3>
                        <p>formed and secreted after mast cells are activated</p>
                        <ol>
                            <li><strong>Leukotrienes B4, C4, D4:</strong>
                                <ul>
                                    <li>formerly known as SRS-A, slow reacting substance of anaphylaxis</li>
                                    <li>arachidonic acid metabolites structurally related to prostaglandins</li>
                                    <li>contracts bronchioles and increases capillary permeability</li>
                                </ul>
                            </li>
                            <li><strong>Platelet-activating Factor (PAF):</strong>
                                <ul>
                                    <li>synthesized from phospholipids in the cell membranes</li>
                                    <li>active at $10^{10}$M</li>
                                    <li>potent hypotensive agent</li>
                                    <li>most potent bronchorestricting agent in asthma and allergic rhinitis (hay fever)</li>
                                    <li>aggregates and lyses platelets releasing serotonin and other mediators</li>
                                    <li>promotes eosinophil infiltration</li>
                                    <li>PAF antagonists represent an active area of research, particularly for drugs to prevent abnormalities in reproduction</li>
                                </ul>
                            </li>
                            <li><strong>Prostaglandin D2 and other prostaglandins</strong></li>
                        </ol>
                        <h3 class="subsection-heading">Cytokines:</h3>
                        <ul>
                            <li>stimulates production of lymphokines (IL-3, IL-4, IL-5, IL-6, GM-CSF), which stimulate production of leukocytes, more mast cells</li>
                            <li>stimulates production of bradykinin, which causes vasodilation, hypotension</li>
                        </ul>
                        <p><em>Self (This heading seems to be a placeholder or incomplete in the MMD)</em></p>
                        <h3 class="subsection-heading">Systemic Anaphylaxis:</h3>
                        <ul>
                            <li>most severe and life-threatening type of allergic response</li>
                            <li>characteristics:
                                <ul>
                                    <li>generalized flush, palpitations, dizziness, apprehension, urticaria, angioedema and abdominal cramps</li>
                                    <li>may proceed to dyspnea, seizures, cyanosis, shock, and/or death</li>
                                </ul>
                            </li>
                            <li>begins 3 to 4 min after administration</li>
                            <li>causes:
                                <ul><li>xenogenic sera, allergenic extracts, dextrans, therapeutic enzymes, polypeptide hormones, penicillins and cephalosporins.</li></ul>
                            </li>
                            <li>localized anaphylaxis affects only certain vasodilation smooth muscles most common is hay fever (allergic rhinitis) and asthma (localized bronchial constriction)</li>
                            <li>Skin grids are useful for detecting if a person will respond to an allergen; Risk of sensitizing the individual as well as leading to shock.</li>
                        </ul>
                        <h3 class="subsection-heading">Drugs that Affect TYPE I Hypersensitivity</h3>
                        <ul>
                            <li><strong>Antihistamines:</strong> Block H1&H2 receptors</li>
                            <li><strong>Cromolyn Sodium:</strong> Blocks Calcium influx</li>
                            <li><strong>Theophylline:</strong> Prolongs cAMP levels (inhibits phosphodiesterases). Degranulation is increased by lowering levels of cAMP</li>
                            <li><strong>Epinephrine:</strong> Stimulates cAMP production through $\beta$-adrenergic receptor</li>
                            <li><strong>Cortisone:</strong> Blocks histamine production, stimulates mast cell cAMP production</li>
                        </ul>
                        <h3 class="subsection-heading">Histamine Causes a Wide Array of Effects</h3>
                        <ul>
                            <li>smooth muscle cells - Constriction</li>
                            <li>small blood vessels - Vasodilation</li>
                            <li>mucous glands - Mucous secretion</li>
                            <li>blood platelets</li>
                            <li>sensory nerve endings</li>
                        </ul>
                        <p>Histamine Receptors (H1 and H2 receptors)</p>
                        <h3 class="subsection-heading">Therapeutic Immediate-Hypersensitivity Antigens</h3>
                        <ul>
                            <li>Therapy for allergies based on hyposensitivity</li>
                            <li>Typical therapy depends on the injection of known quantities of an allergen in the hope of increasing the amount of IgG over IgE capable of reacting with the allergen</li>
                            <li>IgG blocks the binding of the allergen with IgE</li>
                        </ul>
                        <h3 class="subsection-heading">Type I Hypersensitivity: Immunomodulation</h3>
                        <figure>
                            <img src="../assets/images/2025_06_15_a488c342de18e7acee23g-20-1.jpg" alt="Diagram explaining immunomodulation in Type I hypersensitivity (allergy shots). Repeated allergen exposure aims to induce IgG (blocking antibody) and regulatory T cells, shifting away from Th2/IgE response." class="content-image">
                        </figure>
                    </div>
                </section>
                <!-- END: section-type-i-hypersensitivity -->

                <!-- START: section-drug-immunopathology-type-i -->
                <section id="section-drug-immunopathology-type-i" class="content-section" aria-labelledby="section-heading-drug-immunopathology-type-i">
                    <h2 id="section-heading-drug-immunopathology-type-i" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Hypersensitivity Induced Drug Immunopathology - Type I</span>
                    </h2>
                    <div class="content-card">
                        <p>Type I= Can cause allergic anaphylactic reaction due to allergen complexation with sensitized Mast cell</p>
                        <figure>
                            <img src="../assets/images/2025_06_15_a488c342de18e7acee23g-21-1.jpg" alt="Diagram illustrating Type I hypersensitivity drug reaction: a drug acts as an allergen, sensitizes mast cells via IgE, and upon re-exposure, causes mast cell degranulation and anaphylactic symptoms." class="content-image">
                        </figure>
                    </div>
                </section>
                <!-- END: section-drug-immunopathology-type-i -->

                <!-- START: section-type-ii-hypersensitivity -->
                <section id="section-type-ii-hypersensitivity" class="content-section" aria-labelledby="section-heading-type-ii-hypersensitivity">
                    <h2 id="section-heading-type-ii-hypersensitivity" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Type II Hypersensitivity</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>The reaction time is minutes to hours</li>
                            <li>Mediated by antibodies of IgM or IgG class</li>
                            <li>Damage mediated by complement or ADCC</li>
                            <li>Endpoint is cell lysis</li>
                            <li>Cells that bind antibodies
                                <ul>
                                    <li>Foreign cells</li>
                                    <li>unfortunate "bystanders" cells binding substances recognizable by antibodies</li>
                                </ul>
                            </li>
                            <li>Antibodies react with foreign antigens on surface of blood cells - Blood groups are sugars connected to lipid (glycolipid) or protein (glycoprotein); have antibodies to groups that are lacking.
                                <div class="table-container">
                                    <table class="content-table">
                                        <caption>ABO Blood Groups and Serum Antibodies</caption>
                                        <thead>
                                            <tr><th>Blood Group</th><th>Serum Abs (IgM)</th></tr>
                                        </thead>
                                        <tbody>
                                            <tr><td>A</td><td>anti-B</td></tr>
                                            <tr><td>B</td><td>anti-A</td></tr>
                                            <tr><td>AB</td><td>none</td></tr>
                                            <tr><td>O</td><td>anti-A, anti-B</td></tr>
                                        </tbody>
                                    </table>
                                </div>
                            </li>
                            <li>Blood cells deemed to be foreign are removed by ADCC</li>
                            <li>Reason for blood transfusion reaction</li>
                            <li>Other blood antigen Rhesus blood group (Rh(D); 85% are RhD+ and 15% are RhD -) results in Rh incompatibility (erythroblastosis fetalis); treatable with RhoGam.</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_06_15_a488c342de18e7acee23g-24-1.jpg" alt="Diagram illustrating mechanisms of Type II hypersensitivity: A) Complement-mediated lysis of target cell after antibody binding. B) Antibody-dependent cell-mediated cytotoxicity (ADCC) where Fc receptor-bearing cells (e.g., NK cells) kill antibody-coated target cells. C) Antibody interference with cell receptor function (e.g., anti-acetylcholine receptor antibodies in Myasthenia Gravis)." class="content-image">
                        </figure>
                        <h3 class="subsection-heading">Rho(D) Immune Globulin (RhIG)</h3>
                        <p><strong>Antigen Source:</strong> Human erythrocytes with Rho(D) surface antigen.</p>
                        <p><strong>Production Process:</strong> RhoD- men or sterile women are immunized with Rho(D) cells in order to produce anti-Rho(D) antibodies. The antibodies are harvested from plasma collected from these donors.</p>
                    </div>
                </section>
                <!-- END: section-type-ii-hypersensitivity -->

                <!-- START: section-type-iii-hypersensitivity -->
                <section id="section-type-iii-hypersensitivity" class="content-section" aria-labelledby="section-heading-type-iii-hypersensitivity">
                    <h2 id="section-heading-type-iii-hypersensitivity" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Type III Hypersensitivity a.k.a immune complex hypersensitivity</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>mediated by soluble immune complexes
                                <ul><li>mostly of IgG class, sometimes IgM</li></ul>
                            </li>
                            <li>The antigen may be exogenous (chronic bacterial, viral or parasitic infections), or endogenous (nonorgan specific autoimmunity)</li>
                            <li>The antigen is soluble and not attached to the organ involved.</li>
                            <li>Primary components are soluble immune complexes and complement (C3a, 4a and 5a).</li>
                            <li>Damage is caused by platelets and neutrophils.</li>
                            <li>Reaction may take 3-10 hours after exposure to the antigen</li>
                        </ul>
                        <h3 class="subsection-heading">Mechanism</h3>
                        <ol>
                            <li>Large immune complexes are formed from complement</li>
                            <li>Complexes are deposited on blood vessel walls or tissues</li>
                            <li>Mast-cells bind the complement at specific receptors and are activated</li>
                            <li>Neutrophils are attracted to the site leading to tissue damage</li>
                        </ol>
                        <figure>
                            <img src="../assets/images/2025_06_15_a488c342de18e7acee23g-28-1.jpg" alt="Diagram illustrating Type III hypersensitivity: Formation of antigen-antibody immune complexes, their deposition in tissues (e.g., blood vessel walls), complement activation, neutrophil recruitment, and subsequent tissue damage through enzyme release." class="content-image">
                            <figcaption>Bacteria or Immune complex under Complement Attack, Attack of Bystander Tissues, Neutrophil/Eosinophil Attraction and Attack, Normal Tissues. Examples: Serum Sickness, Arthus Reaction, Rheumatic Fever, Rheumatoid Arthritis, Farmer's and Pigeon's Lung</figcaption>
                        </figure>
                        <figure>
                            <img src="../assets/images/2025_06_15_a488c342de18e7acee23g-29-1.jpg" alt="Figure 7.37 - Diagram showing immune complex deposition in blood vessel wall, leading to complement activation, neutrophil influx, and vasculitis in Type III hypersensitivity." class="content-image">
                            <figcaption>Figure 7.37</figcaption>
                        </figure>
                        <figure>
                            <img src="../assets/images/2025_06_15_a488c342de18e7acee23g-30-1.jpg" alt="Figure 10.30 / Figure 10.29 - Detailed diagram of immune complex-mediated tissue injury: 1. Immune complex formation. 2. Deposition in vessel wall. 3. Complement activation releasing C3a, C5a. 4. Neutrophil chemotaxis and activation. 5. Release of enzymes and ROS causing tissue damage." class="content-image">
                            <figcaption>Figure 10.29 / Figure 10.30 © 2000 Garland Publishing/Elsevier Science</figcaption>
                        </figure>
                        <div class="table-container">
                             <table class="content-table">
                                 <caption>Type III Hypersensitivity: Routes, Diseases, and Deposition Sites</caption>
                                 <thead>
                                     <tr>
                                         <th>Route</th>
                                         <th>Resulting diseases</th>
                                         <th>Site of Immune-complex deposition</th>
                                     </tr>
                                 </thead>
                                 <tbody>
                                     <tr>
                                         <td rowspan="3">Intravenous (high dose)</td>
                                         <td>Vasculitis</td>
                                         <td>Blood vessel walls</td>
                                     </tr>
                                     <tr>
                                         <td>Nephritis</td>
                                         <td>Renal glomeruli</td>
                                     </tr>
                                     <tr>
                                         <td>Arthritis</td>
                                         <td>Joint spaces</td>
                                     </tr>
                                     <tr>
                                         <td>Subcutaneous</td>
                                         <td>Arthus reaction</td>
                                         <td>Perivascular area</td>
                                     </tr>
                                     <tr>
                                         <td>Inhaled</td>
                                         <td>Farmer's lung</td>
                                         <td>Alveolar/capillary Interface</td>
                                     </tr>
                                 </tbody>
                             </table>
                         </div>
                        <figure>
                            <img src="../assets/images/2025_06_15_a488c342de18e7acee23g-31-1.jpg" alt="Figure 10.31 - Illustration of Arthus reaction (localized Type III) showing subcutaneous injection of antigen in a sensitized individual, leading to local immune complex formation, inflammation, and tissue damage." class="content-image">
                            <figcaption>Figure 10.31</figcaption>
                        </figure>
                        <figure>
                            <img src="../assets/images/2025_06_15_a488c342de18e7acee23g-32-1.jpg" alt="Figure 10.32 - Illustration of Farmer's Lung (inhaled Type III) showing inhaled antigen (e.g., mold spores) leading to immune complex formation in alveoli, inflammation, and impaired lung function." class="content-image">
                            <figcaption>Figure 10.32</figcaption>
                        </figure>
                    </div>
                </section>
                <!-- END: section-type-iii-hypersensitivity -->

                <!-- START: section-drug-immunopathology-type-ii-iii -->
                <section id="section-drug-immunopathology-type-ii-iii" class="content-section" aria-labelledby="section-heading-drug-immunopathology-type-ii-iii">
                    <h2 id="section-heading-drug-immunopathology-type-ii-iii" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Hypersensitivity Induced Drug Immunopathology</span>
                    </h2>
                    <div class="content-card">
                        <p><strong>Type II</strong>= Can cause blood cells that are labelled to be removed by complement or ADCC</p>
                        <figure>
                            <img src="../assets/images/2025_06_15_a488c342de18e7acee23g-33-1.jpg" alt="Diagram illustrating Type II drug-induced immunopathology: drug binds to cell surface (e.g., RBC), antibody forms against drug-cell complex, leading to complement-mediated lysis or ADCC." class="content-image">
                        </figure>
                        <p><strong>Type III</strong>= Can cause complement complexation which can lead to innocent bystander reaction in tissues where complexes lodge (i.e., kidney)</p>
                        <figure>
                            <img src="../assets/images/2025_06_15_a488c342de18e7acee23g-34-1.jpg" alt="Diagram illustrating Type III drug-induced immunopathology: drug acts as soluble antigen, forms immune complexes with antibody, complexes deposit in tissues (e.g., kidney glomeruli), causing inflammation and damage." class="content-image">
                        </figure>
                    </div>
                </section>
                <!-- END: section-drug-immunopathology-type-ii-iii -->

                <!-- START: section-type-iv-hypersensitivity -->
                <section id="section-type-iv-hypersensitivity" class="content-section" aria-labelledby="section-heading-type-iv-hypersensitivity">
                    <h2 id="section-heading-type-iv-hypersensitivity" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Type IV Delayed Hypersensitivity</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Thought to be a response to tissue harboring bacteria or parasites.</li>
                            <li>Occurs most commonly with topical agents which react with the skin (contact dermatitis), such as cosmetics, poison oak, chemicals (e.g., pentadecacatechol)</li>
                            <li>Development of sensitized T<sub>DTH</sub> cells, which secrete cytokines capable of activating and attracting macrophages.</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_06_15_a488c342de18e7acee23g-36-1.jpg" alt="Figure 10.34 - Diagram illustrating Type IV (Delayed-Type) Hypersensitivity. Sensitization phase: antigen presented to T cells, leading to memory Th1 cells. Effector phase: re-exposure to antigen activates memory Th1 cells, which release cytokines, attracting and activating macrophages, causing local inflammation and tissue damage." class="content-image">
                            <figcaption>Figure 10.34</figcaption>
                        </figure>
                        <figure>
                            <img src="../assets/images/2025_06_15_a488c342de18e7acee23g-37-1.jpg" alt="Figure 10.35 - Top: Chemical structure of pentadecacatechol (allergen in poison ivy). Bottom: Image of a skin reaction (contact dermatitis) due to poison ivy, a classic example of Type IV hypersensitivity." class="content-image">
                            <figcaption>Figure 10.35 © 2000 Garland Publishing/Elsevier Science</figcaption>
                        </figure>
                        <h3 class="subsection-heading">Therapeutics Based on Type IV Hypersensitivity</h3>
                        <ul>
                            <li>Type IV hypersensitivity is associated with several diseases and conditions, such as tuberculosis, leprosy, leishmaniasis, deep fungal infections, etc.</li>
                            <li>Type IV is also associated with allergic reactions to contact antigens like poison ivy and poison oak</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-type-iv-hypersensitivity -->

                <!-- START: section-drug-immunopathology-type-iv -->
                <section id="section-drug-immunopathology-type-iv" class="content-section" aria-labelledby="section-heading-drug-immunopathology-type-iv">
                    <h2 id="section-heading-drug-immunopathology-type-iv" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Hypersensitivity Induced Drug Immunopathology - Type IV</span>
                    </h2>
                    <div class="content-card">
                        <p>Type IV= Can cause tissues to be labelled (i.e., skin) and inducing cytotoxic T cell response</p>
                        <figure>
                            <img src="../assets/images/2025_06_15_a488c342de18e7acee23g-38-1.jpg" alt="Diagram illustrating Type IV drug-induced immunopathology: drug acts as a hapten, binds to skin proteins, presented by APCs to T cells, leading to DTH reaction (e.g., contact dermatitis) or CTL-mediated damage." class="content-image">
                        </figure>
                    </div>
                </section>
                <!-- END: section-drug-immunopathology-type-iv -->

                <!-- START: section-take-home-message -->
                <section id="section-take-home-message" class="content-section" aria-labelledby="section-heading-take-home-message">
                    <h2 id="section-heading-take-home-message" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Hypersensitivity Reactions: Take Home Message</span>
                    </h2>
                    <div class="content-card">
                        <ol>
                            <li>Allergic or Hypersensitivity reactions result from an non-desirable immune response.</li>
                            <li>Both CMI and AMI are involved in allergic reactions.</li>
                            <li>Complement is an important part of the immune responses ability to combat bacterial infections.</li>
                            <li>Hypersentivity reactions are a major reason for drug induced pathologies.</li>
                        </ol>
                    </div>
                </section>
                <!-- END: section-take-home-message -->

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="immunology-23c-secondary-immunodeficiency-details.html" class="nav-button"> 
                        <span class="nav-icon"></span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 84.62%;"></div> 
                        </div>
                       <span class="progress-text">Lecture 33 of 39</span> 
                    </div>
                    <a href="immunology-24b-type1-hypersensitivity.html" class="nav-button"> 
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon"></span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script> 
</body>
</html>